Bloomage Biotech: Strategically invested Korean INIBO approved

According to Bloomage Biotech, its strategically invested South Korean botulinum toxin INIBO has recently received approval from the National Medical Products Administration, and the company is its exclusive partner for the Chinese mainland market. This business development is another move by Bloomage Biotech to further expand its business areas and improve its pharmaceutical and medical device business layout on the basis of its existing medical aesthetics industry.